Private Equity Firm to Acquire SeraCare for $82M | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – SeraCare Life Sciences has signed a definitive agreement to be acquired by private equity firm Linden Capital Partners for $4 per share, or around $82 million.

The purchase price represents a 25 percent premium to the 30-day volume-weighted average stock price of SeraCare. The Milford, Mass.-based firm, which makes life sciences tools including molecular biomarkers and controls, would become a private company, wholly owned by Linden.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.